Wall Street Zen Downgrades Savara (NASDAQ:SVRA) to Sell

Savara (NASDAQ:SVRA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

SVRA has been the subject of several other reports. Oppenheimer started coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Price Performance

Shares of Savara stock opened at $5.38 on Friday. The company has a market capitalization of $1.11 billion, a P/E ratio of -9.28 and a beta of 0.29. Savara has a 52-week low of $2.92 and a 52-week high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The company has a 50 day moving average of $5.65 and a 200 day moving average of $5.48.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, research analysts forecast that Savara will post -0.62 EPS for the current fiscal year.

Institutional Trading of Savara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its stake in Savara by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after purchasing an additional 16,634 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Savara in the second quarter valued at about $30,000. XTX Topco Ltd acquired a new position in Savara during the 2nd quarter worth $201,000. Invesco Ltd. boosted its stake in shares of Savara by 35.4% in the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after purchasing an additional 31,633 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after purchasing an additional 6,449 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara News Roundup

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.